

Allergy and Immunology

Division Photo



First Row: N. Zimmermann, A. Assa'ad, M. Rothenberg; Second Row: A. Mishra, J.P. Abonia, L. Zuo, YH. Wang, K. von Tiehl, A. Munitz, S. Hogan, K. Risma, M. Lierl

Division Data Summary

Research and Training Details

Number of Faculty	14
Number of Joint Appointment Faculty	2
Number of Research Fellows	7
Number of Research Students	5
Number of Support Personnel	6
Direct Annual Grant Support	\$5,036,336
Direct Annual Industry Support	\$258,157
Peer Reviewed Publications	27
Clinical Activities and Training	
Number of Clinical Staff	1
Number of Clinical Fellows	6
Number of Clinical Students	2
Number of Other Students	6
Inpatient Encounters	595
Outpatient Encounters	6,250

Significant Publications

Groschwitz KR, Ahrens R, Osterfeld H, Gurish MF, Han X, Abrink M, Finkelman FD, Pejler G, Hogan SP. Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proc Natl Acad Sci U S A2009 Dec 29;106(52):22381-6.

Altered intestinal barrier function is postulated to be a central predisposing factor to intestinal diseases, including inflammatory bowel diseases and food allergies. However, the mechanisms involved in maintaining homeostatic

intestinal barrier integrity remain largely undefined. A recent study by Groschwitz et al. identified a mechanism by which mast cells regulate homeostatic intestinal epithelial migration and barrier function. These findings further the basic understanding of intestinal barrier function, which is a necessary precursor to improved disease management and treatment.

Kottyan LC, Collier AR, Cao KH, Niese KA, Hedgebeth M, Radu CG, Witte ON, Khurana Hershey GK, Rothenberg ME, Zimmermann N. Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner. Blood2009 Sep 24;114(13):2774-82.

The microenvironment of the lung in asthma is acidic, yet the effect of acidity on inflammatory cells has not been well established. A recent study by Kottyan et al. demonstrated that acidity inhibits eosinophil apoptosis and increases cellular viability in a dose-dependent manner between pH 7.5 and 6.0, mainly via the G protein-coupled receptor 65 (GPR65). Notably, GPR65-deficient mice had attenuated airway eosinophilia and increased apoptosis in two distinct models of allergic airway disease. These animal model findings hint that reducing the increased eosinophil viability in the acidic microenvironment of the asthmatic lung may alleviate or lessen eosinophil-derived symptoms.

Abonia JP, Blanchard C, Butz BB, Rainey HF, Collins MH, Stringer K, Putnam PE, Rothenberg ME. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol2010 Jun 8.

Eosinophilic esophagitis is an emerging disorder with poorly understood pathogenesis. Whereas prior studies have primarily focused on the role of eosinophils in disease diagnosis and pathogenesis, a recent study by Abonia et al. investigated the involvement of mast cells. The investigators identified local mastocytosis and mast cell degranulation in the esophagi of patients with eosinophilic esophagitis, defined an esophageal mast cell-associated transcriptome that is significantly divergent from the eosinophil-associated transcriptome, and provided evidence for the involvement of KIT ligand in the pathogenesis of eosinophilic esophagitis. These findings unveil several of the further complexities of eosinophilic esophagitis pathogenesis in humans.

Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, Buckmeier BK, Jameson SC, Greenberg A, Kaul A, Franciosi JP, Kushner JP, Martin LJ, Putnam PE, Abonia JP, Wells SI, Rothenberg ME. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol2010 Apr 1;184(7):4033-41.

Aiming to uncover molecular explanations for eosinophilic esophagitis pathogenesis, a recent study by Blanchard et al. compared epithelial responses between healthy patients and those with eosinophilic esophagitis. Their findings establish that the epithelial response in eosinophilic esophagitis involves a cooperative interaction between IL-13 and expression of epithelial differentiation complex genes.

Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, Gober L, Kim C, Glessner J, Frackelton E, Thomas K, Blanchard C, Liacouras C, Verma R, Aceves S, Collins MH, Brown-Whitehorn T, Putnam PE, Franciosi JP, Chiavacci RM, Grant SF, Abonia JP, Sleiman PM, Hakonarson H. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet2010 Apr;42(4):289-91.

Eosinophilic esophagitis is an allergic disorder characterized by the accumulation of eosinophils in the esophagus. A recent study by Rothenberg et al. identified the first association of eosinophilic esophagitis with a chromosomal locus, specifically with variants at 5q22. Gene expression data from esophageal biopsies from individuals with eosinophilic esophagitis compared with unaffected individuals implicate the 5q22 locus in the pathogenesis of eosinophilic esophagitis and identify TSLP as the most likely candidate gene in the region.

Division Highlights

Genetic Region Identified for a Children's Food Allergy

Division director Marc Rothenberg, MD, PhD, post-doctorate Joseph Sherill, PhD, and colleagues have identified the first major gene location responsible for eosinophilic esophagitis (EE), a severe, often painful type of food allergy that leaves its victims unable to eat a wide variety of foods (Rothenberg ME, et al. *Nature Genetics*. 2010;42(4):289-91). The genome-wide analysis studies implicated the 5q22 chromosomal locus in the pathogenesis of EE and identified thymic stromal lymphopoietin (TSLP) as the most likely candidate gene in the region with specific genetic variants in TSLP and its receptor specifically linking with EE compared with other allergic diseases (Sherrill JD, et al. *Journal of Allergy and Clinical Immunology*. 2010;126(1):160-165).

National Registry to Track Eosinophilic Disorders

A \$1.6 million federal economic stimulus grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases has helped to launch the Registry for Eosinophilic Gastrointestinal Disorders (REGID), developed by division director Marc Rothenberg, MD, PhD, along with division faculty Pablo Abonia, MD, and CCHMC co-investigators James Franciosi, MD, and Keith Marsolo, PhD; see www.regid.org. The registry is the first of its kind for eosinophilic disorders and will allow participating centers around the nation to build a database of research-accessible clinical information for thousands of patients coping with eosinophilic disorders.

Interleukin 15 Involved in Eosinophilic Esophagitis

A recent study by associate professor Anil Mishra, PhD, research associate Xiang Zhu, PhD, and colleagues has reported the significance of the induced expression and protein levels of interleukin 15 (IL-15) in human and experimental eosinophilic esophagitis (EE). Notably, transcript levels of IL-15 strongly correlated with esophageal eosinophils in patients with active EE and significantly decreased in patients with improved treated EE, and mouse models of allergen-induced EE demonstrated that the IL-15 receptor, IL-15Ra, was necessary for the development of EE (Zhu X, et al. *Gastroenterology*. 2010;139(1):182-193.e7).

Division Co-director Supports CCHMC's National and Global Mission

During this past year, co-director Amal Assa'ad, MD, has exemplified the national and global mission of Cincinnati Children's Hospital Medical Center (CCHMC) through her far-reaching dedication and valued efforts to improve child health. She has represented CCHMC as an invited speaker at plenary sessions and international symposia at three national meetings in the USA and five international meetings in South America, Europe, Asia, and the Middle East. In addition, she has contributed as a reviewer of the first evidence-based guidelines for food allergy by the World Allergy Organization (WAO), the WAO Diagnosis and Rationale Against Cow Milk Allergy (DRACMA) Guidelines, and as a writer and writing section chair for the NIH Expert Panel on Food Allergy Guidelines.

Mast Cells Regulate Homeostatic Intestinal Epithelial Migration and Barrier Function

A recent study by associate professor Simon Hogan, PhD, graduate student Katherine Groschwitz, and colleagues has identified a chymase / mast cell protease 4 -dependent mechanism by which mast cells regulate homeostatic intestinal epithelial migration and barrier function (Groschwitz et al. *Proceedings of the National Academy of Science of the United States of America*. 2009;106(52):22381-6).

Eosinophil Viability Increased in Acidic Microenvironment

A recent study by associate professor Nives Zimmermann, MD, graduate student Leah Kottyan, and colleagues has demonstrated that acidity inhibits eosinophil apoptosis and increases cellular viability in a dose-dependent manner between pH 7.5 and 6.0, mainly via the G protein-coupled receptor 65 (GPR65). Notably, GPR65-deficient mice had attenuated airway eosinophilia and increased apoptosis in two distinct models of allergic airway disease (Kottyan et al. *Blood*. 2009;114(13):2774-82).

Allergic Reaction to Mecasermin

A recent case report by division co-director Amal Assa'ad, MD, clinical fellow Kelly Metz, MD, and colleagues details the second case of cutaneous and systemic allergic reaction to mecasermin, a recombinant human insulin-like growth factor 1 (IGF-1) approved by the Food and Drug Administration for treatment of growth failure in children with severe primary IGF-1 deficiency (Metz et al. *Annals of Allergy, Asthma & Immunology.* 2009;103(1):82-3.

C-C chemokine receptor type 3 Promising Target for Age-related Macular Degeneration

A recent collaborative research study by division director Marc Rothenberg, MD, PhD, and adjunct assistant professor Ariel Munitz, PhD, has shown promising results for age-related macular degeneration (AMD). Choroidal neovascularsation, the major cause of blindness from AMD, was more effectively reduced by blockade of C-C chemokine receptor type 3 than by blockade of vascular endothelial growth factor A blockade, which is in present clinical use. Additionally, blockade of C-C chemokine receptor type 3 was also less toxic to the retina (Takeda et al. *Nature*. 2009;460(7252);225-30).

T cell Subsets in Experimental Eosinophilic Esophagitis

A recent study by associate professor Anil Mishra, PhD, research associate Xiang Zhu, PhD, and colleagues has demonstrated an imbalance of esophageal effector and regulatory T cell subsets in a mouse model of eosinophilic esophagitis. Esophageal effector T cells increased whereas regulatory T cells decreased in allergen-challenged mice, suggesting that interaction of these T cell subsets may be required for protective and pathogenic immunity in eosinophilic esophagitis (Zhu et al. *American Journal of Physiology – Gastrointestinal and Liver Physiology*. 2009;297(3):G550-8). **Involvement of Mast Cells in Eosinophilic Esophagitis**

Whereas prior studies have primarily focused on the role of eosinophils in disease diagnosis and pathogenesis of eosinophilic esophagitis, the involvement of mast cells was investigated in a recent study by division director Marc Rothenberg, MD, PhD, assistant professor J. Pablo Abonia, MD, and colleagues. The investigators identified local mastocytosis and mast cell degranulation in the esophagi of patients with eosinophilic esophagitis, defined an esophageal mast cell-associated transcriptome that is significantly divergent from the eosinophil-associated transcriptome, and provided evidence for the involvement of KIT ligand in the pathogenesis of eosinophilic esophagitis (Abonia et al. *Journal of Allergy and Clinical Immunology*. 2010;126(1):112-119).

Coordinate Interaction Between IL-13 and Epithelial Differentiation Cluster Genes in Eosinophilic Esophagitis Aiming to uncover molecular explanations for eosinophilic esophagitis pathogenesis, a recent study by division director Marc Rothenberg, MD, PhD, instructor Carine Blanchard, PhD, and colleagues compared epithelial responses between healthy patients and those with eosinophilic esophagitis. Their findings establish that the epithelial response in eosinophilic esophagitis involves a cooperative interaction between IL-13 and expression of epithelial differentiation complex genes (Blanchard et al. *Journal of Immunology*. 2010;184(7):4033-41).

Glucocorticoid-regulated Genes in Eosinophilic Esophagitis

A recent study by division director Marc Rothenberg, MD, PhD, post-doctorate Julie Caldwell, PhD, and colleagues provides evidence that swallowed glucocorticoid treatment directly affects esophageal gene expression in patients with EE. In particular, increased esophageal FK506-binding protein 5 (FKBP51) transcript levels identify glucocorticoid exposure in vivo and distinguish patients with EE who responded to fluticasone propionate treatment from untreated patients with active EE and patients without EE, suggesting that esophageal FKBP51 levels may have diagnostic and prognostic significance in patients with EE (Caldwell et al. *Journal of Allergy and Clinical Immunology*. 2010;125(4):879-88 e8).

Polymorphisms in Sialic Acid-binding Immunoglobulin-like Lectin-8 Associated with Asthma Susceptibility

A recent collaborative research study by division director Marc Rothenberg, MD, PhD, and associate professor Nives Zimmermann, MD, has identified a significant association of polymorphisms in the sialic acid-binding immunoglobulin-like lectin-8 gene with susceptibility to asthma in diverse populations (Gao et al. European Journal of Human Genetics. 2010;18(6):713-9).

Arginase I Suppresses Intestinal Inflammation During Acute Schistosomiasis

A recent collaborative research study by division director Marc Rothenberg, MD, PhD, and associate professor Nives Zimmermann, MD, has identified that macrophage-derived arginase I protects hosts from excessive tissue injury caused by worm eggs during acute schistosomiasis by suppressing interleukin 12 / interleukin 23 p40-driven intestinal inflammation (Herbert et al. *Journal of Immunology*. 2010;184(11):6438-46).

Cationic Amino Acid Transporter 2 Regulates Lung Fibrosis in Allergic Airway Inflammation

Using mouse models of allergic airway inflammation and pulmonary fibrosis, a recent study by associate professor Nives Zimmermann, MD, research assistant Kathryn Niese, and colleagues has identified cationic amino acid transporter 2 as a regulator of fibrotic response in the lung (Niese KA et al. *Respiratory Research*. 2010;11(1):87).

Differential Involvement of Interleukin 9/Interleukin 9 Receptor Pathway in Systemic and Oral Antigeninduced Anaphylaxis

Using mouse models of parenteral and oral antigen-induced anaphylaxis, a recent study by associate professor Simon Hogan, PhD, research assistant Heather Osterfeld, and colleagues has identified that parenteral antigen-induced systemic anaphylaxis is mediated by immunoglobulin G and immunoglobulin E -dependent pathways that can occur independently of interleukin 9 / interleukin 9 receptor signaling, whereas oral antigen-induced anaphylaxis is strictly immunoglobulin E-mediated and requires the interleukin 9 / interleukin 9 receptor signaling pathway (Osterfeld H et al. *Journal of Allergy and Clinical Immunology*. 2010;125(2):469-476.e2).

Persistent Rotavirus Vaccine Shedding in Severe Combined Immunodeficiency: A Reason to Screen

A recent case report by division director Marc Rothenberg, MD, PhD, clinical fellow Burcin Uygungil, MD, and colleagues details a case of persistent rotavirus vaccine shedding in a child with previously undiagnosed severe combined immunodeficiency and highlights the need for neonatal screening measures for severe combined immunodeficiency as this case is not an isolated incident (Uygungil et al. *Journal of Allergy and Clinical Immunology*. 2010;125(1):270-1). Local B Cells and Immunoglobulin E Production in the Esophageal Mucosa in Eosinophilic Esophagitis

A recent study by division director Marc Rothenberg, MD, PhD, post doctorate Maria Vicario-Perez, PhD, and colleagues has demonstrated the heretofore unproven occurrence of both local immunoglobulin class switching to immunoglobulin E and immunoglobulin E production in the esophageal mucosa of patients with eosinophilic esophagitis. Sensitization and activation of mast cells involving local immunoglobulin E may therefore critically contribute to disease pathogenesis (Vicario et al. *Gut.* 2010;59(1):12-20).

Division Collaboration

Collaboration with Gastroenterology; Pathology; Nutrition; Social Work

Collaborating Faculty: Drs. Mitchell Cohen, Philip Putnam and James Franciosi; Dr. Margaret Collins Cincinnati Children's Center for Eosinophilic Disorders (CCED)

Faculty Members

Research Interests: Elucidating the mechanisms of allergic responses especially in mucosal tissues such as the lung and the gastrointestinal tract
J. Pablo Abonia, MD, Research Assistant Professor Research Interests: The role of mast cells in eosinophilic esophagitis
 Amal H. Assa'ad, MD, Professor Clinical ; Clinical Director Research Interests: The occult effect of allergic sensitization to foods on the bronchial hyper-responsiveness seen in asthmatic and the genetic basis of food allergy
Carine Blanchard, PhD, Research Instructor Research Interests: To study food allergy; eosinophilic esophagitis; asthma
Thomas J. Fischer, MD, Adjunct Professor Clinical Research Interests: The pharmacologic management of asthma, immune deficiency diseases
Simon P. Hogan, PhD, Assistant Professor Research Interests: To study allergies, food allergies, eosinophil biology & gastrointestinal inflammation
Michelle B. Lierl, MD, Adjunct Associate Professor Research Interests: To reduce environmental tobacco smoke exposure in children with asthma
 Anil Mishra, PhD, Research Assistant Professor Research Interests: Understanding the mechanism of aeroallergen-induced allergic responses in the lung and lower gastrointestinal tract
Kimberly A. Risma, MD, PhD, Research Assistant Professor Research Interests: The molecular and cellular bases of primary disorders of immune deficiency and dysregulation, especially as it relates to lymphocyte cytotoxicity

Yui-Hsi Wang, PhD, Research Assistant Professor

Nives Zimmermann, MD, Research Associate Professor

Research Interests: The molecular understanding of eosinophil survival in allergic inflammation and asthma

Li Zuo, MD, Instructor Clinical Research Interests: To understand the molecular pathogenesis involved in food allergy related disorders.

Joint Appointment Faculty Members

- Gurjit Khurana Hershey, MD, Professor Asthma Research
- Alexandra Filipovich, MD, Professor Hematology/Oncology Diagnostic Laboratory Primary immunodeficiencies; BMT for primary immunodeficiencies; Hemophagocytic lymphocytosis; Post-BMT immune reconstruction

Clinical Staff Members

• Kalra Harpinder, MD

Trainees

- Gerald Lee, MD, PL-7, Saint Vincent's Catholic Medical Centers, New York
- Kelly Metz, MD, PL-6, University of Cincinnati, Ohio
- Charles DeBrosse, MD, PL-5, Ohio State University, Ohio
- Muthuvel Arumugam, PhD, University of Madras, Chennai, India
- · Julie Caldwell, PhD, University of Cincinnati, Ohio
- Chen Chun-Yu, PhD, University of Rochester, New York
- · Carlos Fernandez Gimenez, MD, Clinical Hospital of Salamanca, Spain
- Eun Jin Lim, PhD, University of Kentucky, Kentucky
- Ariel Munitz, PhD, Hebrew University of Jerusalem, Israel
- Joseph Sherrill, PhD, University of Cincinnati, Ohio
- Zeenath Unnisa, PhD, Osmania University, Hyderabad, India
- Ramon Urrea-Moreno, PhD, Hospital Gregorio Maranon, Madrid, Spain
- Ting Wen, PhD, Rutgers University/UMDNJ, New Jersey
- Katherine Groschwitz, , Xavier University, Ohio
- Hongyan Zhu, , Hubei College of Traditional Medicine, China
- Amanda Beichler, , Ohio Northern University, Ohio
- Tom Lu,, University of Cincinnati, Ohio
- Leah Kottyan, , Huntingdon College, Alabama

۰,,

Significant Accomplishments

Gene region identified for severe food allergy

Director Marc Rothenberg, MD, PhD, and colleagues identified the first major gene location (5q22.1) responsible for susceptibility to eosinophilic esophagitis (EE), a severe food allergy that leaves individuals unable to eat a wide variety of foods. Using a genome-wide gene variation analysis, they identified overexpression of the TSLP gene at this chromosomal location. These data implicate the 5q22 locus in the pathogenesis of EE and identify TSLP as the most likely candidate gene.

National registry to track eosinophilic disorders

A \$1.6 million federal economic stimulus grant from the National Institute of Diabetes and Digestive and Kidney Diseases helped us launch the Registry for Eosinophilic Gastrointestinal Disorders (REGID). It is the first registry to provide the infrastructure for understanding and treating eosinophilic disorders at a national – and ultimately international - level. Rothenberg developed REGID along with division faculty member Pablo Abonia, MD, and co-investigators James Franciosi, MD, and Keith Marsolo, PhD.

Interleukin 15 involved in eosinophilic esophagitis

Anil Mishra, PhD, and colleagues identified the significance of induced expression and protein levels of interleukin 15 (IL-15) in human and experimental EE. The researchers found that transcript levels of IL-15 strongly correlated with esophageal eosinophils in patients with active EE. Likewise, the levels significantly decreased in patients with improved, treated EE. Using mouse models, researchers showed the receptor for IL-15, IL-15Ra, is necessary for the development of EE. Elevated IL-15 levels in the blood samples of EE patients could potentially serve as a diagnostic biomarker.

Division Publications

1. :

rant and Contract Awards		Annual Direct / Project Period Direct
Beichler, A		-
Graduate Student Award 2009		
AGA Foundation for Digestive Heal		
	07/01/09 - 06/30/11	\$20,000 / \$40,000
Blanchard, C		
Urplakin 1b: A Genetic Risk Mark American Partnership for Eosinophi		is
	07/01/09 - 06/30/10	\$25,000 / \$25,000
Caldwell, J		
Molecular Mechanisms of Glucoc American Heart Association	corticoids and FKBP51 in Infla	mmation
09POST2180041	07/01/09 - 06/30/11	\$43,000 / \$88,000
DeBrosse, C		
2009 Fellows Career Developmen	nt Award	
American Academy of Allergy, Asth		
	07/01/09 - 06/30/10	\$50,000 / \$50,000
Groschwitz, K		
Mast Cell-Mediated Intestinal Per	meability	
National Institutes of Health		
F30 DK 082113	07/01/08 - 06/30/11	\$32,588 / \$95,625
Hogan, S		
Interleukin-9 in Experimental Inte	estinal Anaphylaxis	
National Institutes of Health		
R01 AI 073553	04/01/08 - 03/31/12	\$247,500 / \$995,000
Intestinal IL-9 and Mast Cells in		
Food Allergy and Anaphylaxis Netw		
	02/02/09 - 01/31/11	\$124,773 / \$249,546
Kucuk, Z		
Immunology/Allergy Fellowship T		
University of Cincinnati (National In		
T32 AI 060515	07/01/09 - 06/30/11	\$45,048 / \$45,048
Mishra, A		
Role of IL-15 in the Pathogenesis National Institutes of Health	s of Eosinophilic Esophagitis	
R01 AI 080581	07/22/09 - 06/30/11	\$250,000 / \$500,000
Mechanistic Analysis of Eosinop National Institutes of Health	hilic Esophagitis	
R01 DK 067255	07/17/09 - 06/30/11	\$20,000 / \$20,000

The Expression and Function of ILT-3/LIR-5 in Pediatric Eosinophilic Esophagitis Thrasher Research Fund 06/01/09 - 05/31/11 \$14,000 / \$25,00 sma, K The Functional Consequences of Incomplete Perforin Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophaglcytic Lymphohistiocytosis Histiocytosis Association of America		07/01/09 - 09/30/10	\$50,000 / \$50,00
Fegulation of Eosinophils by PIR-B American Heart Association - Ohio Affiliate O825621D 07/01/08 - 06/30/10 \$45,000 / \$88,00 The Expression and Function of ILT-3/LIR-5 in Pediatric Eosinophilic Esophagitis Thrasher Research Fund \$14,000 / \$25,00 Sama, K The Functional Consequences of Incomplete Perfori Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagicytic Lymphohisticorytosis \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagicytic Lymphohisticorytosis \$100,000 / \$300,00 Hemophagicytic Lymphohisticorytosis 01/01/10 - 12/31/10 \$50,000 / \$10,00,00 thenoberg, M IL-13 and Eosinophilic Esophagitis \$1,042,081 / \$1,042,081 National institutes of Health \$1,042,081 / \$1,042,081 \$1,042,081 R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idiopathic Eosinophili Elosofares \$200,200 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis \$10/01/07 - 09/30/10 \$100,000 / \$300,00 The Alergy and Anaphylaxis Network \$202/02/09 - 01/31	nitz A		
American Heart Association - Ohio Affiliate 0825621D 0701/08 - 06/30/10 \$45,000 / \$86,00 The Expression and Function of ILT-3/LIR-5 in Pediatric Eosinophilic Esophagitis Thrasher Research Fund 06/01/09 - 05/31/11 \$14,000 / \$25,00 ma, K The Functional Consequences of Incomplete Perforin Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagicytic Lymphohisticocytosis Histicocytosis Association of America 01/01/10 - 12/31/10 \$50,000 / \$50,000 / \$50,000 thenberg, M IL-13 and Eosinophilic Esophagitis National Institutes of Health Rol DK Or6893 09/01/07 - 06/30/12 \$200,900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis National Institutes of Health Rol DK Or6893 09/01/07 - 06/30/12 \$200,900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis National Institutes of Health Rol DK Or6893 09/30/09 - 06/31/11 \$1,042,081 / \$1,042,081 / \$1,042,081 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human filoipathic Ecoinophilic Disorders The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilis Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses National Institutes of Health Rol JA 03850 09/20/09 - 07/31/14 \$225,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health Rol JA 08806 12/01/09 - 11/30/14 \$225,000 / \$1,247,50 Regulations of Food Allergies Research Program Department of Defense WitWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,87 Audit-Center Clinical Trial of 1760 mg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 09/26/09 - 08/31/11 \$409,241 / \$612,182 A Mult-Center Clinical Trial of 1760 mg of Daily Swallowed Fluticasone vs. Placebo National Statutes of Health U01 Al 088806 09/26/09 - 08/	-		
The Expression and Function of ILT-3/LIR-5 in Pediatric Eosinophilic Esophagitis Thrasher Research Fund 06/01/09 - 05/31/11 \$14,000 / \$25,00 sma, K The Functional Consequences of Incomplete Perforin Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagleytic Lymphohisticeytosis Histocytosis Association of America 01/01/10 - 12/31/10 \$50,000 / \$50,00 IL-13 and Eosinophilic Esophagitis ILand Eosinophilic Esophagitis ILand Eosinophilic Esophagitis ILand Eosinophilic Esophagitis Land Eosinophilic Esophagitis National Institutes of Health 90/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 \$10,042,081 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idopathic Eosinophilic Disorders The Dana Foundation \$20,000 / \$1,020,00 The Boah Soundation 02/02/09 - 01/31/11 \$62,386 / \$124,77 \$20,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophilis National Institutes of Health \$20,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophilis \$2			
Thrasher Research Fund 06/01/09 - 05/31/11 \$14,000 / \$25,00 ma, K The Functional Consequences of Incomplete Perforin Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagicytic Lymphohisticytosis Histocytosis Association of America 11:13 and Eosinophilic Esophagitis 01/01/10 - 12/31/10 \$50,000 / \$50,00 It-13 and Eosinophilic Esophagitis 09/01/07 - 06/30/12 \$200,900 / \$1,020,90 Li-13 and Eosinophilic Esophagitis 09/01/07 - 06/30/12 \$200,900 / \$1,020,90 Li-13 and Eosinophilic Esophagitis National Institutes of Health \$10,042,081 / \$1,042,081 / \$1,042,081 / \$1,042,081 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idiopathic Eosinophilic Disorders The Dana Foundation The Dana Foundation 02/02/09 - 01/31/11 \$62,386 / \$124,77 Regulations of Gastrointestinal Eosinophilis S20,000 / \$1,247,50 Regulations of Gas	0825621D	07/01/08 - 06/30/10	\$45,000 / \$88,00
06/01/09 - 05/31/11 \$14,000 / \$25,00 sma, K The Functional Consequences of Incomplete Perforin Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagicytic Lymphohisticocytosis \$100,000 / \$50,00 Proteolytic Maturation of America 01/01/10 - 12/31/10 \$50,000 / \$50,00 IL-13 and Eosinophilic Esophagitis National Institutes of Health \$200.900 / \$1,020,90 Roi DK 076893 09/01/07 - 06/30/12 \$200.900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis \$100,100 - 09/30/10 \$1,042,081 / \$1,042,081 National Institutes of Health \$1001 K0 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idiopathic Eosinophilic Disorders \$100,000 / \$300,00 The Dana Foundation 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses National Institutes of Health Roi J & 03/350 08/20/09 - 07/31/14 \$225,000 / \$1,27,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health R01 A 036360 0		R-5 in Pediatric Eosinophilic Esoph	agitis
The Functional Consequences of Incomplete Perforin Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagleytic Lymphohisticocytosis 11/01/10 - 12/31/10 \$50,000 / \$50,000 Itsitocytosis Association of America 01/01/10 - 12/31/10 \$50,000 / \$50,000 \$50,000 / \$50,000 Itsitocytosis Association of America 01/01/10 - 02/31/10 \$200.900 / \$1,020,900 \$100,000 / \$300,900 It-13 and Eosinophilic Esophagitis National Institutes of Health \$10,042,081 / \$1,042,081 / \$1,042,081 \$10,042,081 / \$1,042,081 National Institutes of Health National Institutes of Health \$100,000 / \$300,00 \$100,000 / \$300,00 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Institutes of Health \$20,200 - 01/31/11 \$1,042,081 / \$1,042,081 Rood Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$20,300 / \$1,247,50 Regulations of Gastrointestinal Eosinophili \$200,000 / \$1,247,50 \$200,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophilis \$200,000 / \$1,247,50 \$200,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophilis		06/01/09 - 05/31/11	\$14,000 / \$25,00
The Functional Consequences of Incomplete Perforin Processing American Academy of Allergy, Asthma & Immunology 07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagleytic Lymphohisticocytosis 11/01/10 - 12/31/10 \$50,000 / \$50,000 Itsitocytosis Association of America 01/01/10 - 12/31/10 \$50,000 / \$50,000 \$50,000 / \$50,000 Itsitocytosis Association of America 01/01/10 - 02/31/10 \$200.900 / \$1,020,900 \$100,000 / \$300,900 It-13 and Eosinophilic Esophagitis National Institutes of Health \$10,042,081 / \$1,042,081 / \$1,042,081 \$10,042,081 / \$1,042,081 National Institutes of Health National Institutes of Health \$100,000 / \$300,00 \$100,000 / \$300,00 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Institutes of Health \$20,200 - 01/31/11 \$1,042,081 / \$1,042,081 Rood Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$20,300 / \$1,247,50 Regulations of Gastrointestinal Eosinophili \$200,000 / \$1,247,50 \$200,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophilis \$200,000 / \$1,247,50 \$200,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophilis	ma K		
07/01/09 - 06/30/12 \$100,000 / \$300,00 Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagicytic Lymphohisticocytosis Histiocytosis Association of America 01/01/10 - 12/31/10 \$50,000 / \$50,00 Itemabagity \$50,000 / \$50,00 \$50,000 / \$50,00 Mational Institutes of Health National Institutes of Health \$200,900 / \$1,020,90 Rot DK 076893 09/01/07 - 06/30/12 \$200,900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis National Institutes of Health Rot DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,080 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idopathic Esophagitis Food Allergy and Anaphylaxis Network The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses National Institutes of Health R01 Al 083450 08/20/09 - 07/31/14 \$250,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Eogramment of Defense W81XWH1010167 03/01/10 - 02/28/12 \$246,436	The Functional Consequences of Incomp		
Proteolytic Maturation of Perforin: Determining the Requirements for Cytotoxic Function in Patients with Hemophagicytic Lymphohisticoytosis Histicoytosis Association of America 01/01/10 - 12/31/10 \$50,000 / \$50,000 thenberg, M IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/01/07 - 06/30/12 \$200.900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/01/07 - 06/30/12 \$200.900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 / \$1,042,081 \$100,000 / \$300,00 IL-13 and Eosinophilic Disorders The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$20,200 / \$1,247,50 IL-13 Associated Eosinophil Lung Responses National Institutes of Health R01 Al 083450 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Genetic Studies of Food Allergies Research Program Department of Defense WaltXWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,83 Aduti-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00	American Academy of Amergy, Astrina & imi		\$100 000 / \$300 00
Hemophagicytic Lymphohistiocytosis Histiocytosis Association of America 01/01/10 - 12/31/10 \$50,000 / \$50,000 thenberg, M IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/01/07 - 06/30/12 \$200.900 / \$1,020,900 IL-13 and Eosinophilic Esophagitis National Institutes of Health \$1,042,081 / \$1,042,081 R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idiopathic Eosinophilic Disorders The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,000 The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses National Institutes of Health R01 Al 083450 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health National Institutes of Health R01 Al 045898 12/01/09 - 11/30/14 \$225,000 / \$1,125,000 S246,436 / \$492,83	Brotophytic Maturation of Porforing Datarn		
01/01/10 - 12/31/10 \$50,000 / \$50,00 thenberg, M IL-13 and Eosinophilic Esophagitis National Institutes of Health \$200,900 / \$1,020,90 R01 DK 076893 09/01/07 - 06/30/12 \$200,900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis National Institutes of Health \$1,042,081 / \$1,042,081 / \$1,042,081 R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,081 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idiopathic Eosinophilic Disorders The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis 502/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses 02/02/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health 80/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health 80/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health 80/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National In	Hemophaglcytic Lymphohistiocytosis		
IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/01/07 - 06/30/12 \$200.900 / \$1,020.90 IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,08 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idiopathic Eosinophilic Disorders The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network 2/02/09 - 01/31/11 \$62,386 / \$124,75 IL-13 Associated Eosinophil Lung Responses 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils 8225,000 / \$1,125,00 Regulations of Gastrointestinal Eosinophils National Institutes of Health 12/01/09 - 11/30/14 \$225,000 / \$1,125,00 Roti Al 083450 08/20/09 - 03/31/11 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Pepartment of Defense W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,82 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 09/26/09 - 08/31/11 \$409,241 /	····,	01/01/10 - 12/31/10	\$50,000 / \$50,00
IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/01/07 - 06/30/12 \$200.900 / \$1,020.90 IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,08 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Idiopathic Eosinophilic Disorders The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network 2/02/09 - 01/31/11 \$62,386 / \$124,75 IL-13 Associated Eosinophil Lung Responses 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils 8225,000 / \$1,125,00 Regulations of Gastrointestinal Eosinophils National Institutes of Health 12/01/09 - 11/30/14 \$225,000 / \$1,125,00 Roti Al 083450 08/20/09 - 03/31/11 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Pepartment of Defense W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,82 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 09/26/09 - 08/31/11 \$409,241 /	henberg, M		
National Institutes of Health R01 DK 076893 09/01/07 - 06/30/12 \$200.900 / \$1,020,90 IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$250,000 / \$1,247,75 / \$250,000 / \$1,247,75 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,247,50 / \$250,000 / \$1,245,00 / \$250,000 / \$1,245,00 / \$250,000 / \$1,245,00 / \$250,000 / \$1,245,00 / \$250,000 / \$1,245,00 / \$250,000 / \$1,245,00 / \$250,000 / \$1,245,00 / \$20,00 /			
IL-13 and Eosinophilic Esophagitis National Institutes of Health R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,08 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Humar Idiopathic Esosinophilic Disorders The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis 2/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses 08/20/09 - 07/31/14 \$250,000 / \$1,247,56 Regulations of Gastrointestinal Eosinophils 08/20/09 - 07/31/14 \$250,000 / \$1,247,56 Regulations of Gastrointestinal Eosinophils 03/01/10 - 02/28/12 \$246,436 / \$492,87 Attional Institutes of Health 70/01/10 - 02/28/12 \$246,436 / \$492,87 Roy and Institutes of Food Allergies Research Program 220/20/9 - 08/31/11 \$409,241 / \$612,14 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health 70 U01 Al 088806 09/26/09 - 08/31/11 \$409,241 / \$612,14 \$409,241 / \$612,14 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo	National Institutes of Health		
National Institutes of HealthR01 DK 07689309/30/09 - 08/31/11\$1,042,081 / \$1,042,081R01 DK 07689309/30/09 - 08/31/11\$1,042,081 / \$1,042,081Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Humar diopathic Eosinophilic DisordersThe Dana Foundation10/01/07 - 09/30/10\$100,000 / \$300,00The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network02/02/09 - 01/31/11\$62,386 / \$124,77IL-13 Associated Eosinophil Lung Responses National Institutes of Health08/20/09 - 07/31/14\$250,000 / \$1,247,50Regulations of Gastrointestinal Eosinophils National Institutes of Health12/01/09 - 11/30/14\$225,000 / \$1,247,50Regulations of Gastrointestinal Eosinophils National Institutes of Food Allergies Research Program Department of Defense2/02/09 - 03/31/11\$246,436 / \$492,81A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 08880609/26/09 - 08/31/11\$409,241 / \$612,11A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 08880606/28/10 - 05/31/11\$90,000 / \$90,00Childia Genes in Allergic Inflammation - Project #2\$246,430 / \$90,000 / \$90,00	R01 DK 076893	09/01/07 - 06/30/12	\$200.900 / \$1,020,90
R01 DK 076893 09/30/09 - 08/31/11 \$1,042,081 / \$1,042,080 Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Information Focusing on Siglec-8 for the Diagnosis and Treatment of Human Information Focusing on Siglec-8 for the Diagnosis and Siglec-8 for the Diagnosi Siglec-8 for the Diagnosis and Siglec-8 for the Diagno			
Novel Genetic and Therapeutic Approaches Focusing on Siglec-8 for the Diagnosis and Treatment of Human Information Internation 10/01/07 - 09/30/10 State 10/01/07 - 09/30/10 The Dana Foundation 10/01/07 - 09/30/10 The Data Foundation 10/01/07 - 09/30/10 The Role of CREB Binding Protein in Eosinophilic Esophagitis 5 Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 02/02/09 - 01/31/11 \$62,386 / \$124,7 IL-13 Associated Eosinophil Lung Responses National Institutes of Health R01 Al 083450 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health 7 R01 Al 045898 12/01/09 - 11/30/14 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Department of Defense W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,81 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 06/28/10 - 05/31/11 \$409,241 / \$612,11 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 06/28/10 - 05/3			
Idiopathic Eosinophilic Disorders 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Dana Foundation 10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses 02/02/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils Regulations of Gastrointestinal Eosinophils Regulations of Gastrointestinal Eosinophils National Institutes of Health 701/09 - 11/30/14 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Pepartment of Defense W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,83 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 06/28/10 - 05/31/11 \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 06/28/10 - 05/31/11 \$409,000 / \$90,00 V01 Al 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 <td< td=""><td></td><td></td><td></td></td<>			
10/01/07 - 09/30/10 \$100,000 / \$300,00 The Role of CREB Binding Protein in Eosinophilic Esophagitis Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses National Institutes of Health \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$225,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$225,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$225,000 / \$1,247,50 Genetic Studies of Food Allergies Research Program \$225,000 / \$1,125,00 Department of Defense \$246,436 / \$492,83 W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,83 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 09/26/09 - 08/31/11 \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 U01 Al 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inf	Idiopathic Eosinophilic Disorders	es Focusing on Siglec-8 for the Di	agnosis and Treatment of Human
Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses National Institutes of Health 8250,000 / \$1,247,50 Ro1 Al 083450 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$250,000 / \$1,247,50 National Institutes of Health 801 2/01/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$250,000 / \$1,247,50 National Institutes of Health 801 Al 045898 12/01/09 - 11/30/14 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program \$225,000 / \$1,125,00 \$246,436 / \$492,87 Department of Defense \$246,436 / \$492,87 \$246,436 / \$492,87 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 National Institutes of Health \$90,000 / \$90,00 \$90,000 / \$90,00 U01 Al 088806 \$06/28/10 - 05/31/11 \$90,000 / \$90,00 National Institutes of Health \$90,000 / \$90,00 \$90,000 / \$90,00 U01 Al 088806 \$06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 \$90,000 / \$90,00 National Institutes of Healt		10/01/07 - 09/30/10	\$100,000 / \$300,00
Food Allergy and Anaphylaxis Network 02/02/09 - 01/31/11 \$62,386 / \$124,77 IL-13 Associated Eosinophil Lung Responses National Institutes of Health 8250,000 / \$1,247,50 Ro1 Al 083450 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$250,000 / \$1,247,50 National Institutes of Health 801 2/01/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils \$250,000 / \$1,247,50 National Institutes of Health 801 Al 045898 12/01/09 - 11/30/14 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program \$225,000 / \$1,125,00 \$246,436 / \$492,87 Department of Defense \$246,436 / \$492,87 \$246,436 / \$492,87 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 National Institutes of Health \$90,000 / \$90,00 \$90,000 / \$90,00 U01 Al 088806 \$06/28/10 - 05/31/11 \$90,000 / \$90,00 National Institutes of Health \$90,000 / \$90,00 \$90,000 / \$90,00 U01 Al 088806 \$06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 \$90,000 / \$90,00 National Institutes of Healt			
IL-13 Associated Eosinophil Lung Responses National Institutes of Health 8250,000 / \$1,247,50 Ro1 Al 083450 08/20/09 - 07/31/14 \$250,000 / \$1,247,50 Regulations of Gastrointestinal Eosinophils National Institutes of Health \$225,000 / \$1,247,50 Ro1 Al 045898 12/01/09 - 11/30/14 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Department of Defense \$246,436 / \$492,87 W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,87 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health \$409,241 / \$612,18 U01 Al 088806 09/26/09 - 08/31/11 \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health \$90,000 / \$90,00 U01 Al 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 Pithelial Genes in Allergic Inflammation - Project #2 \$90,000 / \$90,00	The Role of CREB Binding Protein in Eos	inophilic Esophagitis	
National Institutes of Health8250,000 / \$1,247,50Regulations of Gastrointestinal Eosinophils\$250,000 / \$1,247,50National Institutes of HealthR01 AI 04589812/01/09 - 11/30/14\$225,000 / \$1,125,000Rot AI 04589812/01/09 - 11/30/14\$225,000 / \$1,125,000\$225,000 / \$1,125,000Genetic Studies of Food Allergies Research ProgramDepartment of Defense\$246,436 / \$492,837W81XWH10016703/01/10 - 02/28/12\$246,436 / \$492,837A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo\$409,241 / \$612,180National Institutes of Health09/26/09 - 08/31/11\$409,241 / \$612,180U01 AI 08880606/28/10 - 05/31/11\$90,000 / \$90,000U01 AI 08880606/28/10 - 05/31/11\$90,000 / \$90,000Kational Institutes of Health\$90,000 / \$90,000\$90,000 / \$90,000U01 AI 08880606/28/10 - 05/31/11\$90,000 / \$90,000Kational Institutes of Health\$90,000 / \$90,000\$90,000 / \$90,000U01 AI 08880606/28/10 - 05/31/11\$90,000 / \$90,000Kational Institutes of Health\$90,000 / \$90,000\$90,000 / \$90,000Kational Institutes of Health\$90		inophilic Esophagitis	
R01 AI 08345008/20/09 - 07/31/14\$250,000 / \$1,247,50Regulations of Gastrointestinal Eosinophils National Institutes of Health2250,000 / \$1,247,50R01 AI 04589812/01/09 - 11/30/14\$225,000 / \$1,125,00Genetic Studies of Food Allergies Research Program Department of Defense W81XWH1010167\$246,436 / \$492,87A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806\$99,26/09 - 08/31/11A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806\$99/26/09 - 08/31/11Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806\$99/26/09 - 08/31/11Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806\$99/26/09 - 05/31/11Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806\$90,000 / \$90,000U01 AI 088806\$90,000 / \$90,000Epithelial Genes in Allergic Inflammation - Project #2 National Institutes of Health			\$62,386 / \$124,77
Regulations of Gastrointestinal Eosinophils National Institutes of Health R01 AI 045898 12/01/09 - 11/30/14 S225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Department of Defense W81XWH1010167 03/01/10 - 02/28/12 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806 09/26/09 - 08/31/11 V01 AI 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 National Institutes of Health	Food Allergy and Anaphylaxis Network	02/02/09 - 01/31/11	\$62,386 / \$124,77
National Institutes of Health R01 AI 045898 12/01/09 - 11/30/14 \$225,000 / \$1,125,00 Genetic Studies of Food Allergies Research Program Department of Defense \$246,436 / \$492,83 W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,83 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 National Institutes of Health 09/26/09 - 08/31/11 \$409,241 / \$612,18 U01 AI 088806 09/28/10 - 05/31/11 \$409,241 / \$612,18 U01 AI 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 \$90,000 / \$90,00	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health	02/02/09 - 01/31/11 nses	
R01 Al 04589812/01/09 - 11/30/14\$225,000 / \$1,125,00Genetic Studies of Food Allergies Research Program Department of Defense W81XWH101016733/01/10 - 02/28/12\$246,436 / \$492,87A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 08880699/26/09 - 08/31/11\$409,241 / \$612,18A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 08880690/26/09 - 08/31/11\$409,241 / \$612,18Epithelial Genes in Allergic Inflammation - Project #2 National Institutes of Health90,000 / \$90,00	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health	02/02/09 - 01/31/11 nses	
Genetic Studies of Food Allergies Research Program Department of Defense W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,87 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 National Institutes of Health 09/26/09 - 08/31/11 \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$90,000 / \$90,00 National Institutes of Health 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 National Institutes of Health \$90,000 / \$90,00	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14	
Department of Defense 03/01/10 - 02/28/12 \$246,436 / \$492,83 W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,83 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 09/26/09 - 08/31/11 \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 National Institutes of Health 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 \$409,241 / \$612,18	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14	\$250,000 / \$1,247,50
W81XWH1010167 03/01/10 - 02/28/12 \$246,436 / \$492,83 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 09/26/09 - 08/31/11 \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,18 National Institutes of Health 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 \$409,241 / \$612,18	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14	\$250,000 / \$1,247,50
A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806 09/26/09 - 08/31/11 \$409,241 / \$612,18 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 AI 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Research	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14	\$250,000 / \$1,247,50
National Institutes of Health 09/26/09 - 08/31/11 \$409,241 / \$612,12 A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo \$409,241 / \$612,12 National Institutes of Health 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 \$409,241 / \$612,12	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Resear Department of Defense	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00
A Multi-Center Clinical Trial of 1760 mcg of Daily Swallowed Fluticasone vs. Placebo National Institutes of Health U01 Al 088806 06/28/10 - 05/31/11 \$90,000 / \$90,00 Epithelial Genes in Allergic Inflammation - Project #2 National Institutes of Health	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Researe Department of Defense W81XWH1010167	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program 03/01/10 - 02/28/12	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00 \$246,436 / \$492,8
National Institutes of Health06/28/10 - 05/31/11\$90,000 / \$90,00U01 AI 08880606/28/10 - 05/31/11\$90,000 / \$90,00Epithelial Genes in Allergic Inflammation - Project #2National Institutes of Health	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon- National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Research Department of Defense W81XWH1010167 A Multi-Center Clinical Trial of 1760 mcg	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program 03/01/10 - 02/28/12	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00 \$246,436 / \$492,8
National Institutes of Health06/28/10 - 05/31/11\$90,000 / \$90,000U01 AI 08880606/28/10 - 05/31/11\$90,000 / \$90,000Epithelial Genes in Allergic Inflammation - Project #2National Institutes of HealthProject #2	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon- National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Researd Department of Defense W81XWH1010167 A Multi-Center Clinical Trial of 1760 mcg National Institutes of Health	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program 03/01/10 - 02/28/12 of Daily Swallowed Fluticasone vs	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00 \$246,436 / \$492,87 • Placebo
Epithelial Genes in Allergic Inflammation - Project #2 National Institutes of Health	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon- National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Researd Department of Defense W81XWH1010167 A Multi-Center Clinical Trial of 1760 mcg National Institutes of Health U01 Al 088806	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program 03/01/10 - 02/28/12 of Daily Swallowed Fluticasone vs 09/26/09 - 08/31/11	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00 \$246,436 / \$492,8 • Placebo \$409,241 / \$612,18
National Institutes of Health	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Researd Department of Defense W81XWH1010167 A Multi-Center Clinical Trial of 1760 mcg National Institutes of Health U01 Al 088806 A Multi-Center Clinical Trial of 1760 mcg	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program 03/01/10 - 02/28/12 of Daily Swallowed Fluticasone vs 09/26/09 - 08/31/11	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00 \$246,436 / \$492,8 • Placebo \$409,241 / \$612,18
U19 AI 070235 09/15/06 - 07/31/11 \$182,955 / \$874,22	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon- National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophil National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Researd Department of Defense W81XWH1010167 A Multi-Center Clinical Trial of 1760 mcg National Institutes of Health U01 Al 088806 A Multi-Center Clinical Trial of 1760 mcg National Institutes of Health	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program 03/01/10 - 02/28/12 of Daily Swallowed Fluticasone vs 09/26/09 - 08/31/11 of Daily Swallowed Fluticasone vs	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00 \$246,436 / \$492,87 • Placebo \$409,241 / \$612,18 • Placebo
	Food Allergy and Anaphylaxis Network IL-13 Associated Eosinophil Lung Respon National Institutes of Health R01 Al 083450 Regulations of Gastrointestinal Eosinophi National Institutes of Health R01 Al 045898 Genetic Studies of Food Allergies Researd Department of Defense W81XWH1010167 A Multi-Center Clinical Trial of 1760 mcg National Institutes of Health U01 Al 088806 A Multi-Center Clinical Trial of 1760 mcg National Institutes of Health U01 Al 088806 Epithelial Genes in Allergic Inflammation	02/02/09 - 01/31/11 nses 08/20/09 - 07/31/14 ils 12/01/09 - 11/30/14 ch Program 03/01/10 - 02/28/12 of Daily Swallowed Fluticasone vs 09/26/09 - 08/31/11 of Daily Swallowed Fluticasone vs 06/28/10 - 05/31/11	\$250,000 / \$1,247,50 \$225,000 / \$1,125,00 \$246,436 / \$492,87 • Placebo \$409,241 / \$612,18 • Placebo

	Total \$5,294,49	
	Current Year Direct Receipts	\$ 258,15
Merck & Co, Inc.		\$ 19,25
Novartis Pharmaceuticals		\$ 27,32
Rothenberg, M		Ψ 2 11,07
Abonia, P Ception Therapeutics, Inc.		\$ 211,57
dustry Contracts	Current Year Direct	\$5,036,33
R21 AI 088559	03/03/10 - 02/29/12	\$125,000 / \$275,00
Role of Acidity and GPR65 in Food Al National Institutes of Health	llergy	
	07/01/09 - 06/30/10	\$3,000 / \$3,00
Assessing Eosinophil Survival in Acio University of Cincinnati	lic Environments Modeling the Asthmatic Lung	
R21 AI 079251	02/15/09 - 01/31/11	\$148,500 / \$273,50
Role of Acidic Environment in Eosino National Institutes of Health	philic Inflammation	
Zimmermann, N		
Regulation of TH2 Memory/Effector Co National Institutes of Health R01 AI 090129	ells During Allergic Inflammation 05/01/10 - 04/30/15	\$250,000 / \$1,250,00
University of Cincinnati (National Institute KL2 RR 026315	07/01/09 - 03/31/10	\$83,928 / \$83,9
Wang,Y CTSA KL2 Scholar Award		
National Institutes of Health K12 HD 028827	04/01/07 - 11/30/11	\$400,000 / \$2,000,00
Strauss, A / Rothenberg, M Pediatric Center for Gene Expression	and Development	